AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2020
Jun 19, 2020
33148_dirs_2020-06-18_a8720422-0483-474c-b187-54b8fafee91a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2020-06-16
Reporting Person: Makker Gotham (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-06-16 | Stock Option (Right to Buy) | $19.9 | A | 20000 | Acquired | 2030-06-16 | Common Stock (20000) | Direct |
| 2020-06-16 | Stock Option (Right to Buy) | $19.9 | A | 9784 | Acquired | 2030-06-16 | Common Stock (9784) | Direct |
| 2020-06-16 | Stock Option (Right to Buy) | $19.9 | A | 3206 | Acquired | 2030-06-16 | Common Stock (3206) | Direct |
Footnotes
F1: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021.
F2: This option represents a right to purchase a total of 9,784 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021.
F3: This option represents a right to purchase a total of 3,206 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. This option was issued to the Reporting Person in lieu of director retainer fees of $39,000.